[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503467":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":21,"responsibleParty":41,"collaborators":44,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":7,"enrollmentInfo":58,"targetDuration":7,"studyType":61,"phases":7,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":75,"whyStopped":7,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Pontificia Universidad Catolica de Chile","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Maria E Ceballos, MD","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+56996739404","meceball@uc.cl",{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},"Jimena L Flores, RN","+56993158486","jflores@med.puc.cl",[22],{"facility":23,"status":7,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"CICUC","Santiago","Santiago Metropolitan","3830000","Chile","CL",{"type":30,"coordinates":31},"Point",[32,33],-70.64827,-33.45694,{"lat":33,"lon":32},[36,37,38],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"name":18,"role":14,"phone":19,"phoneExt":7,"email":20},{"name":39,"role":40,"phone":7,"phoneExt":7,"email":7},"Alvaro M Rojas, MD","SUB_INVESTIGATOR",{"type":11,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Maria Elena Ceballos","MD, Assistant Professor School of Medicine",[45],{"name":46,"class":47},"ViiV Healthcare","INDUSTRY","100503467","switch-from-oral-therapy-to-long-acting-injectable-cabotegravir--rilpivirine-100503467",false,"NCT05835635","Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine","Level of Satisfaction and Quality of Life in People Living With HIV in Chile, Who Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine","CABO-LA","Inclusion Criteria:\n\nAll patients who, according to the recommendations for use, can receive LA- injectable Cabotegravir +Rilpivirine therapy will be invited to participate in the study.\n\nRecommendations for use:\n\n* HIV-1 positive patients, on antiretroviral therapy\n* Older than 18 years of age at the time of signing the informed consent\n* Undetectable HIV viral load in the last 6 months\n* Willing to switch from oral to injectable therapy\n\nExclusion Criteria:\n\nThese criteria are defined for those patients who, according to the recommendations for use, cannot receive the therapy:\n\n* Previous virological failure\n* Any evidence of primary resistance or the presence of any major known INI or NNRTI resistance-associated mutation by any historical resistance test result.\n* Patients with decompensated pathology (physical or mental) or active opportunistic infection at the time of admission\n* Concomitant use with: rifampin, carbamazepine, oxcarbazepine, phenytoin and phenobarbital or any contraindication to one of the drugs of the study\n* Known hepatitis B co-infection\n* Pregnancy (There is insufficient data for people who become pregnant on CAB or those planning to conceive because available pregnancy PK data are limited (n = 3), and data on clinical outcomes in pregnancy are extremely limited. Therefore, CAB is Not Recommended for pregnant or nonpregnant people initiating or restarting ART or for those whose current regimen is not well tolerated and\u002For not fully suppressive)","ALL","18 Years",{"count":59,"type":60},50,"ESTIMATED","OBSERVATIONAL","This protocol will assess the level of satisfaction, acceptance of treatment and quality of life of patients with undetectable HIV who voluntarily change from oral to injectable antiretroviral treatment at 72 weeks of follow-up.",[64,65,66,67],"Patient Satisfaction","Patient Preference","Quality of Life","Acceptability of Health Care",[69,70,71,72,73,74],"Quality of life","Acceptability","Satisfaction","Preference","HIV","Long acting- cabotegravir","NOT_YET_RECRUITING","2024-11-05",{"date":78,"type":79},"2024-11-07","ACTUAL",{"date":81,"type":60},"2025-05-01",{"date":83,"type":60},"2026-05-01",{"name":5,"class":6},1]